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Summary  
Uveal melanoma (UM) is the most common primary intraocular malignancy occurring in 
adults. Despite successful treatment of the primary tumour approximately 50% of patients 
develop liver metastases. Typically, liver metastases are detected 1-3 years after ocular 
treatment. Sometimes the metastasis appears 10 or even 20 years after primary tumour 
treatment. The reason for such latency is yet to be understood. One hypothesis is that a subset 
of stem-like cancer cells remain dormant and are reactivated after many years. They then 
proliferate and give rise to the bulk of the tumour. Cancer stem cells (CSCs) are cells with the 
capacity to divide asymmetrically to produce another CSC and a daughter cell that gives rise 
to the bulk of the tumour. In addition to the key properties of CSCs of self-renewal and 
differentiation, they also possess features that enable them to generate, maintain, enhance 
tumour growth and resist conventional therapy. These include expression of putative stem 
cell markers, activation of embryonic signalling pathways, anoikis resistance/anchorage 
independent growth, dye/drug efflux, and the ability to change their metabolic signature 
among others. The aims of this thesis were to identify CSCs in UM, particularly their 
phenotypic profile and role in this disease.  
To this end, I examined the expression of CSC and adhesion markers in normal choroidal 
melanocytes (NCM), UM cell lines and in primary UM cells (PUM) grown in adherent and 
non-adherent culture conditions. Several CSC markers; CD166, Nestin and CD271 were 
upregulated in high metastatic risk PUM compared with low metastatic risk PUM and NCM. 
Cells surviving anoikis showed increased expression of these markers. A tumour migration 
assay showed that a CD166high subpopulation isolated from a UM cell line had higher 
migratory capacity compared to the CD166low population. The data generated in this section 
identified putative CSC markers in UM.  
The results of this thesis also showed that neural crest (NC) developmental/embryonic 
markers are expressed in UM, suggesting that these primitive pathways may be reactivated in 
this tumour. Detailed investigations of Nestin, a neural stem cell marker in UM patient tissue 
showed that increased expression of Nestin significantly correlates with known poor 
prognostic factors, such as epithelioid cell morphology, high mitotic count, the presence of 
closed connective loops, monosomy 3 and polysomy 8q. Nestin is also expressed in 
metastatic UM (MUM), which together with previous studies showing Nestin expression in 
circulating tumour cells, suggests that Nestin may be used as a biomarker in high-risk UM 
patients for early detection of disseminated disease.  
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Introduction 
1.1. Incidence 
 
Uveal melanoma (UM) is a malignant tumour thought to arise from an uncontrolled division 
and proliferation of melanocytes within the uveal tract, comprising the iris, ciliary body and 
choroid. The uveal tract is the vascularised middle layer of the eye between the sclera and 
retina(1). Although a rare tumour, UM is the most common primary intraocular tumour in 
adults.   
UM occurs in about 6-8 individuals per million each year (2). It accounts for about 5% of all 
melanomas in humans (3). Fair-skinned populations are more affected than others, especially 
those with blue or grey eyes and blonde or red hair with cutaneous freckles or nevi (4). UM is 
seen more commonly in older people with only 1% being reported in patients of 18 years and 
under (5). The incidence of UM rises with increasing age, with more than 20 cases per 
million per year being reported in individuals aged 70 years and above (2). Males and 
females are affected equally (3).  
In this introduction, the anatomy, diagnosis, treatment and prognostication of UM as well as 
an overview of metastatic UM will be discussed. Further on, a brief outline of the 
development of melanocytes will be given as well as the concept of stem cells in normal 
tissue and cancer. 
1.2. Anatomical and clinical features of UM 
1.2.1. Choroidal Melanoma 
 
The choroid is the largest part of the uvea, located in the posterior part of the eye. It is 
comprised of blood vessels, melanocytes, fibroblasts, resident immunocompetent cells and 
supporting collagenous and elastic connective tissue. Its functions include providing oxygen 
and nutrients to the outer retina, light absorption, thermoregulation, modulation of intraocular 
pressure (IOP) and drainage of aqueous humour (6). Ninety percent of UM arise from this 
region (Fig. 1.1.) (7). Choroidal melanomas may remain restricted by the Bruch’s membrane 
and thereby have a “dome shaped” pattern resulting in small retinal detachment and 
deposition of lipofuscin in the subretinal space. If the tumour breaks through Bruch’s 
membrane, it may appear as a “collar-stud‟ or “mushroom” shape and leads to subretinal 
exudation, and typically to a large retinal detachment. This is one of the pathognomonic 
clinical features of the disease (8).  
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1.2.2. Ciliary Body Melanoma  
The ciliary body is an anterior extension of the choroid. It is made up of two structures: the 
ciliary muscle and the ciliary processes. The latter are ridge-like structures that increase the 
surface area for aqueous humour secretion. The ciliary muscle and ciliary processes make up 
the pars plicata (Latin: folded portion), which is the anterior portion of the ciliary body. The 
pars plana (Latin: flat portion) is the posterior area of the ciliary body: it has no known 
function after birth and is often used as an entry site during vitrectomy(1).  
Five percent of UM develop in the ciliary body (Fig. 1.1) (7). Ciliary body melanomas tend 
to be diagnosed later than choroidal ones because they present with visual symptoms later 
and may be overlooked if dilation of the pupil is not undertaken during routine 
ophthalmological examinations. Presenting symptoms may include unilateral cataract, 
elevated IOP, and dilated episcleral vessels in the corresponding eye. Visual field defects do 
not occur until the tumour is large enough to cause obstruction of the pupil (9).  
 
1.2.3 Iris melanoma 
The iris is the diaphragm separating the anterior chamber from the posterior chamber. It is the 
anterior most part of the uvea and is in front of the lens. Its contraction and dilation, which is 
influenced by the sphincter and dilator muscles respectively, influence the amount of light 
entering the eye through the pupil. The iris also determines the eye colour due to the melanin 
in the posterior pigment epithelium (10).  
Iris melanomas are often small nodular lesions that are deeply pigmented (Fig. 1.1). The 
anatomic location allows for earlier detection. Diffuse iris melanoma, which is a rare, more 
aggressive variant of the tumour may also occur. It typically causes glaucoma by obstructing 
the aqueous outflow pathway, including the trabecular meshwork and Schlemm’s canal. Such 
iris melanomas have an increased risk of metastasis (9).  
1.3 Diagnosis and Treatment  
1.3.1. Signs, symptoms and diagnosis 
 
Blurred vision, flashing lights or shadows, opaqueness of the lens, and glaucoma may be the 
first symptoms that patients experience. Upon visiting an optometrist or ophthalmologist, the 
diagnosis of UM would be made after a slit lamp, direct ophthalmoscope examination, 
ultrasonography or optical coherence tomography (OCT) (11). For many patients, the 
diagnosis is made during routine eye examination as the tumour may not present any 
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symptoms. Pain is experienced in <1% of cases and may be due to increased IOP from iris 
neovascularization or closed angle glaucoma. (12). 
Characterisation of the tumour size is often performed by ultrasonography. Traditionally, this 
was based on the largest basal diameter (LBD). This classification has been updated in the 8th 
Tumour, Node and Metastasis (TNM) staging system, devised by the American Joint 
Committee on Cancer (AJCC), which is an anatomical staging system applied in all cancers 
(13). It enables the UM to be staged based not only by its LBD and thickness, but also by its 
extraocular extension (EOE) and/or ciliary body involvement (CBI) (14). Different examples 
of the shape, size and location of UM are shown in Fig. 1.2.  
 
 
Figure 1.1 Anatomical location and clinical appearance of UM. A) Choroidal melanoma; B) 
Ciliary body melanoma; C) Iris melanoma (Courtesy of Prof. B. Damato). 
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Figure 1.2 H&E examples of the different sizes, shapes and locations of UM at 4x 
magnification. (A) Ciliary body melanoma, (B) Ciliochoroidal melanoma, (C) Choroidal 
melanoma, (D) Large choroidal melanoma, (E) Dome shaped choroidal melanoma, (F) 
Collar-stud choroidal melanoma, (G) Choroidal melanoma with optic nerve involvement, (H) 
Ciliochoroidal melanoma with extraocular extension (Courtesy of Prof. Coupland). 
 
1.3.2. Treatment  
 
After the diagnosis of UM, management options are offered to the patient according to the 
tumour size and its location. Associated ocular co-morbidities and patient preference are 
other factors considered when determining UM treatment. Currently available treatment 
options include forms of radiotherapy, surgical excision, enucleation or phototherapy 
(reviewed by (15)).    
Posterior UM are most commonly treated by radiotherapy. Brachytherapy using a radioactive 
plaque of Ruthenium-106 is most widely used in Europe, while the Iodine-125 isotope is the 
most popular in the USA (16). Tumour control is rated at 90% within 5 years using this 
treatment (17, 18). Side effects of radiotherapy including radiation retinopathy, exudative 
retinal detachment, neovascular glaucoma and radiation maculopathy may be experienced in 
some patients depending on radiation dose and isotope used(19, 20). This may lead to a 
secondary enucleation in 12-17% of cases (19).  
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Proton beam radiotherapy (PBR) is offered to patients in some specialised centres. It involves 
focusing a beam of radiation from an external source onto the tumour while sparing the 
surrounding tissue (21). It is modified to suit the tumour based on its size (between 2.5 and 
10 mm in height and <16 mm basal diameter) (22) and location, and may be used for any 
UM, including iris melanomas (18). The region of radiation is marked by tantalum markers 
which are small inert metal buttons sutured to the sclera overlying the tumour. The patient is 
then placed in a fixed position, the eye is monitored with X-ray to visualise the markers and 
the radiation is administered (23). PBR is very effective in controlling UM; however, visual 
loss may occur, especially if the optic nerve or macula region are irradiated (24, 25).  
Fractionated stereotactic radiotherapy is another treatment option that is widely available for 
the treatment of UM. It involves the use of a gamma knife, cyber knife or linear accelerator 
as the source of radiation. Doses of about 40 Gy in one fraction has been shown to result in 
acceptable local tumour control and low toxicity levels (26). The challenge of this treatment 
modality remains to be the high incidence of radiation-based complications, particularly 
neovascular glaucoma, resulting in secondary enucleation (27). 
The two surgical techniques used to remove UM are called endoresection and ‘exo’ local 
resection. The former involves a pars plana vitrectomy after phacoemulsification with 
intraocular lens implantation. A 25-gauge cutter is used to cause posterior vitreous 
detachment and the choroidal tumour is ‘hoovered’ through the retina. Exoresection or local 
resection involves a partial lamellar sclera-uvectomy technique (28).  To improve local 
control, adjuvant brachytherapy is commonly done after primary tumour resections (29).  
Transpupillary thermotherapy and photodynamic therapy are two of the phototherapeutic 
treatment modalities available in UM management. Reviews show that the success of 
photodynamic therapy is higher in small, lightly pigmented or amelanotic choroidal 
melanomas and vascular tumours (30). Larger UM are not to be treated with this therapy 
(31). Transpupillary thermotherapy uses an infrared laser (810nm) which delivers heat at 45°-
65°C, increasing the temperature of the tumour cells for about one minute. This disrupts their 
metabolic activity and coagulates the blood vessels (32). The efficacy of this treatment 
method has however been questioned as a study found that out of 391 patients, 42% of them 
had an intraocular recurrence. It is therefore recommended for only small choroidal 
melanomas with no more than two risk factors like lipofuscin, subretinal fluid, acoustic 
hollowness among others (33).  
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1.4. Prognostication 
Approximately 50% of UM patients develop metastasis, most commonly to the liver. 
Personalised prognostication to determine metastatic risk, is available based on clinical, 
histopathological and genetic features of the tumour (34). This makes it possible to estimate 
the survival probability of an individual patient at the time of ocular treatment.  
1.4.1. Clinical and histopathological features  
 
The size of UM at the time of diagnosis influences prognosis because larger tumours have 
been known to be more aggressive (35). EOE, anterior location with CBI are predictors of a 
worse prognosis. These features are all included in the ‘T’ category of the TNM 
classification. In a study involving 7731 patients, results showed that the risk of metastasis 
and death increases two-fold with each increasing category from T1 to T4. The categories 
increase with increasing tumour base diameter and thickness. In addition, letters (a-d) are 
given depending on whether the tumour has CBI or EOE (36).  
Histopathological analysis of formalin-fixed paraffin-embedded (FFPE) tumour sections after 
haematoxylin & eosin (H&E) staining also provides valuable prognostication data. The cell 
type of the melanoma cells whether epithelioid, spindle or mixed type based on the Callender 
classification is examined (Fig.1.3) (37). Epithelioid cells of polygonal shape, abundant 
cytoplasm, and poor cohesiveness are associated with a higher metastatic risk as compared to 
spindle cells, which are fusiform and in fascicles parallel to each other. Melanoma cells are 
part of a biological spectrum and histologic classification is subjective to some extent.  
 
Figure 1.3. H&E stains showing epithelioid and spindle UM cells. (40x magnification) 
(Courtesy of Prof. Coupland).  
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The mitotic count of the cells seen in H&E, together with the presence of closed connective 
tissue loops also determine the metastatic potential of UM (38). The mitotic count correlates 
with the proliferation rate of the tumour: the higher the number of mitotic figures, the worse 
the prognosis (38).  
Increased metastatic risk is also associated with Period Acid Schiff (PAS) staining of the 
extracellular matrix of connective tissue closed loops. These ‘loops’ are a pattern of 
vasculogenic mimicry in the tumour (39). Other histopathological features of prognostic 
value include presence of tumour infiltrating lymphocytes, degree of pigmentation and 
presence/absence of necrosis (9).  
1.4.2. Genetic profile.  
1.4.2.1. Chromosomal aberrations 
 
Copy number variations (CNVs) are seen in Chromosomes 1, 3, 6 and 8 in a large number of 
UM (40). These chromosomal aberrations can be used for prognostication. Several genetic 
analysis techniques have been used to detect CNVs. Patients seen at the Liverpool Ocular 
Oncology Centre are offered genetic testing of their UM, which is undertaken currently by 
multiplex-ligation-dependent amplification (MLPA) and microsatellite analysis (MSA). 
MLPA allows for relative quantification of multiple loci on chromosomes 1p, 3, 6 and 8 in a 
single reaction, increasing the cost effectiveness of the screening test. If the DNA from the 
sample is not sufficient for MLPA, MSA is performed to determine chromosome 3 status 
(40).  
The loss of one copy of chromosome 3, i.e. monosomy 3 (M3), is the most important 
chromosomal abnormality in UM. It reduces the survival probability from 100% to less than 
50% (41). The gain of the long arm of chromosome 8 (8q gain) is also associated with poor 
prognosis. A MLPA analysis of data from 452 UM patients undertaken by our group reported 
that M3 or 8q gain have a similar impact on survival when occurring alone (42). If a patient 
has both genetic alterations, the 5-year cumulative survival rate is reduced to 30% (43). The 
deletion of chromosome 1p is found in about 30% of UM (44). It shortens disease-free 
survival time if it occurs together with M3 (44). In contrast to the poor prognosis associated 
with chromosome 1p, 3 and 8 aberrations, polysomy 6p, (gain of 6p) is associated with 
prolonged survival and is commonly found in disomy 3 (D3) tumours.  
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1.4.2.2. Other genetic alterations 
 
Unlike skin melanoma, UM has a low mutational burden and low levels of aneuploidy in the 
tumour cells. There is also no evidence of UV-light DNA damage in UM (45). The Mitogen 
Activated protein kinases (MAPK) pathway is activated in >80% of UMs by exclusive 
mutations in the G-coupled cell surface receptors: Guanine nucleotide-binding protein G(q) 
subunit alpha (GNAQ) or subunit alpha-11 (GNA11). These are gain-of function mutations 
that cause the MAPK pathway to be constitutively active (46). 
The BRCA1-associated protein 1 (BAP1) plays a significant role in UM. The BAP1 gene is 
located on chromosome 3 (3p21.31-p21.2) and encodes for a nuclear protein of the 
deubiquitinating enzyme family (47). This tumour suppressor protein is involved in several 
cellular processes including DNA repair, cell cycle regulation and protein trafficking. 
Dysregulation of these processes contributes to tumour development and progression (48). 
We have previously shown that loss of nuclear expression of BAP1 (nBAP1) in UM patients 
correlates with poor prognostic clinicopathological and genetic features and results in a 
reduced survival (49). In another study investigating the cellular expression of BAP1 and 
correlating it to prognosis, our group has shown that loss of nBAP1 expression is the 
strongest prognostic marker in UM (50). These data have been supported by findings from 
other studies including those by (51) (52) and the recent UM data from The Cancer Genome 
Atlas (TCGA) (53). IHC for nBAP1 expression is routinely performed at the Royal Liverpool 
Hospital NHS Trust to aid in UM prognostication. 
1.5. Dissemination, detection and treatment of metastatic UM  
 
Unfortunately, about 50% of UM patients develop metastasis despite successful treatment of 
the primary tumour. Metastatic spread is via the blood stream since the eye has no lymphatic 
drainage. Local dissemination of the tumour rarely occurs especially if the conjunctiva is 
intact and has not been infiltrated transclerally (54).  
The liver is the main site for the metastatic dissemination of UM occurring in around 90% of 
cases. Other sites such as the lung, bone, skin occur occasionally but typically after liver 
metastasis (55). This observation led to the hypothesis that the liver provides a niche for the 
metastatic UM. Hence the former has been named the ’soil’ and the latter the ‘seed’ in 
Paget’s theory of metastasis, which was first described by Ernst Fuchs in 1882 (56).  
Tumour doubling time and mathematical analysis suggests that metastatic spread occurs 
years before the primary UM is large enough to be detected clinically. Occult 
16 
 
micrometastases may be present in UM patients at the time of ocular treatment. Detectable 
metastatic tumours are present at the time of ocular diagnosis in only 1-2% of patients (57). 
Typically, liver metastases are detected 1-3 years after ocular treatment. Sometimes the 
metastasis appears 10, 20 even 40 years after primary tumour treatment. The reason for such 
latency is yet to be understood (58). Theories suggest that a subset of stem-like cancer cells 
remain dormant and are reactivated after many years. They then proliferate and give rise to 
the bulk of the tumour leading to a clinically detectable metastasis.  
Once liver metastasis has developed, median survival time ranges from 2-12 months with 1-
year survival being only 10-15% (59). Patients typically die from parenchymal invasion of 
the metastasis or from toxicity of the chemotherapeutic drugs. Recently, targeted systemic 
therapies, immunotherapies and local-regional treatments are being investigated for the 
treatment of metastatic UM. The best results regarding survival have been seen in patients 
with localised liver disease who are diagnosed early and undergo localised liver resection. 
Early detection of metastatic disease may aid in improving survival (9). 
1.5.1 Screening tools for metastatic UM. 
 
Ultrasound (US) and magnetic resonance imaging (MRI) are the most common imaging tools 
used for screening of metastatic UM. US has a high specificity but low sensitivity for the 
detection of metastatic lesions in the liver (60). It therefore needs to be supplemented with 
other tests if used for follow-up or screening. In Liverpool, the high risk (HR) UM patients 
are offered a liver MRI, which has enabled pre-symptomatic detection of liver disease in 92% 
of patients (61). There is a significant cost of MRI and it cannot be used as a life-long 
monitoring system for all UM patients. Liver function tests (LFTs) are also used to detect 
asymptomatic liver metastasis. The major disadvantage, however, is that the LFTs have a low 
specificity (27%) despite their high sensitivity (90-96%). This is because they are markers of 
liver damage, which may be caused by other substances such as cholesterol-lowering drugs or 
alcohol (62). 
There is a need for more research to enable better understanding, monitoring and 
management of UM. One area that may benefit from more insight would be to identify the 
cell of origin of UM, and subsequently how tumourigenesis is initiated in these cells. There is 
no conclusive evidence to show where UM arises from. The most common theory is that UM 
arises from the malignant transformation of normal uveal melanocytes (63). Melanocytes 
differentiate from non-pigmented precursors called melanoblasts. These neural crest (NC) 
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derived melanoblasts migrate during embryogenesis from the neural plate border into the eye. 
Upon reaching the eye, the cells terminally differentiate to mature melanocytes and/or remain 
as immature melanocytic stem cells as evidenced in the skin (64). These primitive and 
migratory progenitor cells may undergo epigenetic and genetic changes to result in a 
malignant transformation. Alternatively, the mature and differentiated melanocytes may 
undergo dedifferentiation to become more ‘stem-like’, taking on the properties of their 
progenitor cells. Mutations in these cells may lead to cancer (65).  
1.6. Developmental and migratory properties of melanocytes 
 
The NC is a transient embryonic cell population that is from the ectodermal germ layer. The 
cells initially reside at the dorsal neural plate border during gastrulation. As neurulation 
begins, the neural plate begins to close in order to form the neural tube (66). The NC cells are 
elevated coming to eventually lie at the dorsal aspect of the neural folds. At this point, these 
cells express neural crest genes, namely FOXD3 and SOX10 marking their specificity as NC 
cells (66). After neural tube closure, the NC cells begin a process of epithelial-to-
mesenchymal (EMT) transition and migrate to different locations in the developing embryo 
(66). The EMT process involves the loss of cell-cell adhesion, cytoplasmic remodelling and 
morphological changes that allow the NC cells to emigrate from the neuroepithelium. During 
migration, they acquire cell-surface receptors, metalloproteases and cell adhesion molecules 
that enable them to respond properly to cell–cell interactions and environmental cues in their 
migration path. Once the NC cells arrive at their destination, they self-aggregate and begin 
terminal differentiation (67). NC cells generate elements of the craniofacial skeleton, sensory 
and autonomic ganglia of the peripheral nervous system, and skin pigment cells. The specific 
cells include chondroblasts and osteoblasts, adipocytes, neurons and glial cells, cells of the 
adrenal medulla and melanocytes (66) (Fig. 1.4).  
Melanocyte lineage specification from NC cells is governed mostly by the microphthalmia-
associated transcription factor (MITF) (68). This has been supported by studies showing that 
mice lacking MITF do not form melanocytes and the same is true in fish [10]. MITF 
transcriptional targets include genes for melanosomes (melanin containing organelles), 
melanin synthesis pathway and survival genes such as Bcl2 (69). Germline mutations of 
MITF in humans leads to Waardenburg syndrome or Tietz syndrome characterised by lack of 
pigmentation and deafness, due to defects in otic melanocytes (69). PAX3 and SOX10 act 
synergistically to activate MITF (70). These two transcription factors also specify glial cells. 
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The downregulation of FOXD3 and SOX2 is what specifies the melanocyte lineage in the 
bipotent melanoblast glial progenitor cells (68).  
 
 
 Figure 1.4 Neural crest origin, migration and differentiation. Figure taken from Simoes-
Costa, M. & M.E. Bronner, 2015(66).  
 
1.7. Stem cells in normal tissue and cancer.  
The development of the embryo relies heavily on a group of cells with self-renewal and 
multi-lineage differentiation potential. These cells can undergo asymmetric cell division 
generating one daughter cell that retains the self-renewal and multi-lineage differentiation 
capacity while the other can become committed to a specific differentiation pathway (71). 
Stem cells in adult tissue also produce transient amplifying progenitor cells with the ability to 
undergo a limited number of cell divisions before finally differentiating terminally (71). The 
first evidence of stem cells was from the haematopoietic stem cells (HSC) (72). A single HSC 
was able to regenerate the blood system of a mouse. The transient amplifying progenitor 
cells, however, did not have self-renewal properties. When transplanted into an irradiated 
mouse, it could only produce cells for a short period of time (73). 
There are striking similarities between normal organogenesis and carcinogenesis. Many of 
the oncogenes are known to promote self-renewal in normal stem cells and some tumour 
19 
 
suppressor genes also inhibit self-renewal in non-tumour tissue (74). Theories have therefore 
been proposed that cancer originates from deregulated stem cells or mature differentiated 
cells that have dedifferentiated and gained self-renewal properties. The consensus on which 
of these theories is correct is yet to be reached (reviewed by (75)). However, compelling 
evidence for the existence of stem cells in cancer has been provided. The American 
Association for Cancer Research (AACR) held a workshop to review this evidence, providing 
guidelines and defining several terms in this rapidly growing field. They gave the definition 
that cancer stem cells (CSCs) are cells with the capacity to divide asymmetrically to produce 
another CSC and a daughter cell that differentiates giving rise to the bulk of the tumour (76). 
CSCs may also be referred to as tumour initiating cells (TICs), describing their more 
functional role i.e. the capacity to form tumours when xenotransplanted (reviewed by (77)) 
In addition to the properties of self-renewal and differentiation, CSC/TIC also possess certain 
features that enable them to generate, maintain, enhance tumour growth and resist 
conventional therapy. These include expression of putative stem cell markers, activation of 
embryonic signalling pathways, anoikis resistance/anchorage independent growth, dye/drug 
efflux, EMT and the ability to change their metabolic signature among others (reviewed by 
(77)). Several of these properties have been used to identify and isolate CSCs in different 
cancers.  
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2. Aims of this study  
 
1. To investigate the presence of CSC in UM by examination of several properties including 
the expression of putative stem cell markers, reactivation of developmental pathways and 
anoikis resistance.  
2. To examine the expression of CSC- and adhesion markers in normal choroidal 
melanocytes (NCM), UM cell lines and in primary UM (PUM) cells grown in adherent and 
non-adherent culture conditions.  
3. To examine if CSC markers influence patient outcome using the TCGA database.  
4. To investigate the functional role of CSCs in UM cell lines.  
5. To investigate if the developmental/stem cell markers that control cell proliferation and 
migration are expressed in UM tissue.  
6. To investigate if the developmental/stem cell markers have an influence on UM 
prognostication and patient outcome by examining PUM and metastatic uveal melanoma 
(MUM) tissue.   
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3. Materials and Methods  
 
3.1. Sample Collection  
 
The globes of human cadavers were enucleated with consent at the Department of Pathology, 
University of Szeged and the Centre for Eye Research, University of Oslo, Norway. These 
eyes were used for cornea isolation and transplantation according to the ethically approved 
protocol of the Cornea and Tissue Bank in Oslo (REK ref.nr.:2017/418). After isolation of 
the cornea, normal choroidal melanocytes (NCM) were isolated and cultured, according to 
standard protocol that is described below under ‘’Cell culture’’.  
Primary UM (PUM) samples were obtained from the Ocular Oncology Biobank (REC Ref 
16/NW/0380) and Metastatic UM (MUM) samples were obtained from the Liverpool Bio-
innovation Hub Biobank. They were used with patient consent and according to project 
specific ethical approvals from the Health Research Authority (REC Refs 11/NW/0759 and 
15/SS/0097).  
Human Umbilical Vein Endothelial Cells (HUVECs) were kindly donated by Professor Lu-
Gang Yu of the University of Liverpool. This study was approved by the Health Research 
Authority and conducted in accordance with the Declaration of Helsinki. 
3.2. Reagents  
 
The reagents used for cell culture included products from Sigma-Aldrich (Dorset, UK): 
Penicillin/ Streptomycin, DMEM media, Dispase II, Glutamine, Collagenase IV, Collagenase 
I, Phosphate-Buffered Saline (PBS) and Bovine Serum Albumin (BSA). We obtained the 
following reagents from Life Technologies (Warrington, UK): Trypsin/EDTA, Roswell Park 
Memorial Institute (RPMI)-1640 media and non-enzymatic dissociation solution. The Fetal 
Calf Serum (FCS) was purchased from Labtech International Ltd (Heathfield, UK). For 
HUVEC cell culture, EGM-Plus media from Lonza (Slough, UK) was used. The NCM were 
cultured in melanocyte growth media (MGM) from Promocell (Heidelberg, Germany). 
Additional reagents for flow cytometry included: paraformaldehyde (PFA) (Leica 
Microsystems, Milton Keynes, UK), Tween-20 (Fisher Scientific, Loughborough, UK) and 
normal goat serum (Vector Laboratories Ltd, Peterborough, UK). All the fluorescence-
conjugated antibodies were from Biolegend (London, UK). The tissue culture treated flasks 
were from Thermo Scientific (Runcorn, UK) while the ultra-low attachment (ULA) flasks 
were purchased from Sigma (Dorset, UK). Flow cytometry readings were done on the FACS 
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Canto II cytometer from BD Bioscience. The FACS was done on the FACS Aria machine 
from the same company.  
The CD166 and Nestin antibodies used for Western blot and IHC were purchased from 
Abcam (Cambridge, UK). All the reagents for the Western blot were from Biorad (Deeside, 
UK) except for the chemiluminescence reagents, which were from Thermo Scientific and the 
radioimmunoprecipitation assay (RIPA) buffer from Sigma. All the reagents for cell line IHC 
were from Dako, (Glostrup, Denmark) except the Vector AEC Substrate Kit from Vector 
Laboratories Ltd, Scott’s tap water from Leica Microsystems and DPX mountant from 
Sigma. The human tissue IHC for CD166 was performed on the Bond RXm automated 
system from Leica Microsystems Ltd, (Milton Keynes, UK), which uses the Bond™ Polymer 
Refine Red Detection Kit. All the reagents and protocols for this were provided by the 
company. IHC for Nestin on PUM and MUM tissue was done using the Dako autostainer 
(Dako UK Ltd, Ely, Cambridgeshire, UK) which utilized reagents from the FLEX 
EnVisionTM kit.  
Tumour transendothelial migration assay was carried out on transwell plates from VWR 
International Ltd (Lutterworth, Leicestershire, UK). 
3.3. Cell Culture.  
 
The isolation of the NCM was done according to standard protocol, as previously reported 
(78). Briefly, after enucleation, the eye was put in a Petri-dish and washed with PBS+1% 
penicillin-streptomycin solution. A circumferential incision was made in the sclera, behind 
the limbus and the anterior segment, then the vitreous and sensory neuroretina were removed. 
Following this, trypsin was added inside the eye bulb and it was incubated at 37◦C for 1hr to 
remove the retinal pigment epithelial (RPE) cells. DMEM media was then used to flush the 
trypsin and the RPE were collected with gentle pipetting. The choroid was washed with the 
PBS-antibiotic mix. Following this, the choroid was then peeled from the sclera and placed in 
a petri dish. Subsequently, it was mechanically minced with a blade and re-suspended in a 
solution of 0.2U of Dispase. This was incubated for 18 hrs at 4◦C with mild shaking, then at 
37◦C for 1hr. The wash medium was then added, and the supernatant collected and 
centrifuged. The pellet was then plated onto a 6-well plate in MGM.  
Culture of PUM was performed as previously published (79). The piece of tumour tissue 
obtained from surgery was placed in a petri dish and cut to small pieces using a sterile blade. 
These tissue pieces were then re-suspended in collagenase I and incubated at 37◦C for 1hr. 
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Enzyme activity was stopped by addition of media containing 1:1 αMEM: amnioselect, 10% 
FCS, 2 mM L-glutamine and antibiotics. The solution was centrifuged at 1500rpm for 2 mins. 
The supernatant was discarded and the cell pellet was re-suspended in fresh media and plated 
into a 25cm² flask. The media was changed every three days.  
The UM cell lines, both PUM and metastatic UM (MUM), were maintained in RPMI media 
with 10% FCS, 2mM L-glutamine and penicillin-streptomycin. The cells were passaged once 
a week, and then used when they reached ~60% confluence. At the time of experimental 
analyses the cell lines were mycoplasma free and had STR profiles consistent with previously 
published data. 
HUVEC cells were cultured in a specialised media called EGM from Lonza which contains 
growth factors and supplements such as bovine pituitary extract, hydrocortisone, epidermal 
growth factor (EGF) and antibiotics. The media was changed every three days, and when the 
cells formed a confluent monolayer, they were used for the experiments.  
3.4. Flow cytometry  
 
The NCM and the PUM cells were used for flow cytometry upon reaching ~60% confluency. 
They were detached using collagenase IV and a non-enzymatic dissociation solution, 
respectively. Following this, the blocking buffer (10% FCS, 0.02% EDTA in PBS) was 
added. The cells were centrifuged at 1500rpm for 2 mins and the supernatant removed. A 
flow cytometry buffer (PBS and 1% BSA) was added to the pellet and the cells were counted 
using a haemocytometer. 200,000 cells were then placed into each FACS tube in 100µl of 
flow cytometry buffer. The fluorescent antibody of interest was then added for the direct 
labelling of surface antigens. These included PE-conjugated anti-CD166, PE-conjugated anti-
CD133 and FITC-conjugated anti-CD146. After 30 mins, the sample was washed with PBS 
and centrifuged. The remaining pellet was re-suspended in 500µl of flow cytometry buffer 
and run on the FACS Canto II cytometer.  
Indirect labelling for the intracellular proteins involved cell fixation in 1% PFA for 10 mins. 
After washing with PBS, the cells were permeabilized with 0.5% Tween-20 solution for 10 
mins. Blocking was performed using 10% normal goat serum in a 1% BSA and PBS solution. 
10 mins later, the cells were washed with PBS and the primary antibody was added for 30 
mins. The antibodies labelled indirectly were anti-Melan A, anti-CD271 and anti-Nestin. A 
wash was subsequently performed with PBS followed by a further 30 mins incubation at 
room temperature with a fluorescently conjugated secondary antibody (Goat Anti-Mouse IgG 
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H&L (Alexa Fluor 488) [ab150113]. After a final wash, the sample was re-suspended in 
500µl of flow cytometry buffer and analysed on the FACS Canto II cytometer.  
3.5. Adherent and non-adherent cultures for assessment of anoikis resistance  
 
For the purpose of assessing possible changes in putative CSC marker expression during 
anoikis resistance in the UM cell lines, adherent and non-adherent cultures were employed. 
Briefly, cell lines that had been cultured to ~60% confluence were detached using the non-
enzymatic dissociation solution. The cells were incubated in the solution for 5 mins at 37◦C 
followed by addition of an equal volume of RPMI culture media and centrifugation at 
1500rpm for 2 mins. The cells were counted and 5x105 cells were added to either a 75cm² 
tissue culture treated flask or a 75cm² ULA flask. An equal volume of media was added in 
both flasks. The cells were maintained in these conditions for 72 hrs, and subsequently 
labelled for flow cytometry according to the protocol detailed above.  
3.6. Fluorescence activated cell sorting (FACS)  
 
The Mel270 cell line was used for FACS sorting because it had two distinct subpopulations 
of CD166high and CD166low cells. The cell line was cultured in a 175cm² tissue culture flask 
until it reached ~60% confluence. The cells were dissociated using a non-enzymatic solution 
and counted. A total of 7 million cells were re-suspended in a FACS tube using FACS buffer 
(PBS, 1%BSA, 10%serum). Cells were labelled with the PE-conjugated CD166 antibody 
according to the protocol described under ‘flow cytometry’. After 30 mins, the sample was 
washed with a PBS-based wash buffer and re-suspended in FACS buffer. Cell sorting was 
then performed after establishing the negative and positive gates using a PE-isotype control. 
The post-sorted cells were collected in media and plated into 25cm² flasks for 24hrs.  
3.7. Tumour transendothelial migration assay 
 
To mimic the process of extravasation across an endothelial cell layer into the blood stream a 
tumour transendothelial migration assay was performed as previously described (80). For this 
a 24-well plate with trans-well inserts having membranes with 0.8µm pores was used. Firstly, 
the HUVEC cells were harvested and counted. 30,000 cells were plated into each well insert 
and media changed daily for 3 days. When a confluent monolayer had been formed, the 
Mel270 cells were added. 40,000 cells of the Mel270 cell line were plated onto the HUVEC 
cell layer with media containing 1% FCS on the top while the in the bottom of the chamber 
the media contained 10% serum. This plate was incubated at 37°C for 48 hrs. Afterwards, the 
cell-dissociation and calcein-AM cocktail was added and after a 1hr incubation, the 
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fluorescence was measured at 485nm excitation and 520nm emission wavelengths in a 
GeNios Tecan plate reader (Tecan UK Ltd, Reading, UK).  
3.8. Western Blotting 
 
The specificity of the CD166 and Nestin antibodies used for immunohistochemistry was 
examined by Western blotting. Briefly, UM cell lines were grown to ~60% confluence in an 
adherent plate. Media was removed and the flask washed with cold PBS. RIPA buffer 
together with a protease cocktail inhibitor were added to the flask and a scraper was used to 
detach the cells. The suspension was then incubated on ice for 30 mins. Sonication was 
performed for 3 mins followed by heating at 95°C for 10 mins. After centrifugation at 
14,000rpm, the supernatant was transferred to a new Eppendorf tube and stored at -20°C. The 
protein concentration was determined by a BCA assay (Biorad) according to manufacturer’s 
instructions. 20µg of protein was loaded onto an SDS-PAGE gel and run for 2hrs, followed 
by transfer onto a nitrocellulose membrane of 0.45µm pore size. The membranes were 
blocked for 1 hr at room temperature in a solution of 5% non-fat milk (NFM) powder in 
0.05% TBS-Tween20 (TBST). Overnight incubation in primary antibody (1:1000) diluted in 
5% NFM powder was performed at 4°C. This was followed by three wash steps in TBST and 
a 1hr room temperature incubation with anti-rabbit horseradish peroxidase (HRP) conjugated 
secondary antibody (1:5000). After washing, the membranes were developed with an 
enhanced chemiluminescence kit according to manufacturer’s guidelines. Imaging was 
undertaken on a GeneGnome XRQ Image capture machine.  
 3.9. Immunohistochemistry (IHC) 
 
IHC for CD166 in the enucleated eye sections was performed on the automated Bond RXm 
System. The samples were prepared as 4 µm thick sections cut from FFPE tissue blocks. The 
kit used was the Bond™ Polymer Refine Red Detection, which applied a Fast-Red substrate 
chromogen. The slides were counterstained with haematoxylin and mounted using DPX 
mountant. Normal pancreas tissue sections were used as controls and positive staining in 
these demonstrated a valid IHC run. Slides were scanned using the Aperio CS2 Slide scanner 
from Leica and analysed with the Aperio Image Scope software version 11.2. 
IHC staining for Nestin was performed on 4-µm-thick sections cut from FFPE tissue blocks. 
A Dako Pre-treatment module (Dako, Glostrup, Denmark) was used for dewaxing and heat-
induced epitope retrieval. Slides were incubated in a high pH bath containing EnVisionTM 
FLEX target retrieval solution (Tris/EDTA buffer pH9.0) at 96°C for 20 min, then stained 
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with a primary antibody on an autostainer (Dako UK Ltd, Ely, Cambridgeshire, UK) using 
the FLEX EnVisionTM kit reagents. After being washed with FLEX wash buffer, samples 
were blocked with a FLEX peroxidase block for 5 min and incubated with a primary antibody 
for 30 min. Normal colon tissue sections listed in were used as controls and positive staining 
in these demonstrated a valid IHC run for Nestin. 
IHC staining of UM cell lines grown on chamber slides was performed as follows: 0.2% 
Triton-X in PBS was added to each chamber for 5 mins to permeabilize the cells. After being 
washed with FLEX wash buffer, the samples were blocked with an EnVisionTM FLEX 
peroxidase block for 5 mins and incubated with primary monoclonal antibody for 30 mins.  
After being washed again, both the chamber slides and Nestin slides were incubated with a 
FLEX linker for 15 min. Bound antibody was then detected with horseradish peroxidase 
(HRP) for 20 min and visualized with an AEC Substrate Kit or DAB for 30 min. Sections 
were counterstained with Mayer’s haematoxylin, blued with Scott’s tap water and mounted 
with either AquatexTM aqueous mountant (AEC) or DPX mountant (DAB). Omission of 
primary antibody was used as a negative control. Pictures were taken with the Nikon Eclipse 
Ci (Nikon UK Ltd, Surrey, UK). 
3.10. IHC Scoring  
 
IHC stained slides for all antibodies were scored by three independent observers. The 
percentage of positively-stained tumour cells was determined for all antibodies and this was 
used to grade the staining on a scale of 0-100%. In the Nestin stained slides, positive 
expression in the intratumoural capillary endothelium was also assessed, as either being 
present or absent. 
3.11. Statistical analysis 
 
Statistical analyses were undertaken for all the samples and markers. Categorical variables 
were tested using the Pearson’s Chi-squared test and Fisher’s exact test. A student t-test or 
Mann–Whitney test was used for to examine linear variables where the data did or did not fit 
a normal distribution respectively. To determine the threshold for Nestin positivity, a receiver 
operating curve (ROC) analysis was used. Difference in proportion for marker expression in 
the UM cell lines was assessed by z-statistics. Survival correlation was performed using the 
Kaplan– Meier test. A p-value <0.05 was considered to be statistically significant. All 
analyses were performed using SPSS software (ver.24.0; SPSS Science, Chicago, IL, USA). 
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4. Results  
4.1. Cell culture of primary tissue.  
 
The NCM were cultured until they reached 80% confluence and formed mature cells 
producing pigment. The cells were of spindle morphology with many melanosomes present 
in the cytoplasm. PUM cells showed both spindle and epithelioid morphology (Fig.1.5). 
There were varying amounts of melanin production in these cells consistent with histological 
sections of the primary tumour.  
 
        
Figure 1.5. Representative images of NCM (A) and PUM tissue (B) at passage 0 in culture.  
 
4.2. CD166 and Nestin are upregulated in cultured PUM compared to NCM 
When short term cultures (STC) of both NCM and PUM were investigated by flow 
cytometry, the stem cell markers CD166 and Nestin were found to be upregulated in PUM 
compared to NCM (Fig. 1.6). 
CD166 expression was 4-fold greater in the cultured PUM, (mean 78.3%, median 77.6%, 
range 54.1-99.6%) compared to its expression in the NCM, (mean 18.8%, median 15.5%, 
range 3.5-40.8%). This 4-fold increase in expression was found to be statistically significant 
(p=0.0003; Mann-Whitney). When correlated with chromosomal aberrations and histological 
prognostic factors, CD166 expression did not correlate with any known predictors of survival 
or disease outcome. Nestin expression was 1.6-fold higher in PUM (mean 33.1%, median 
18.5%, range 0.04-99.3%) compared to NCM (mean 19.9%, median 16.5%, range 5.2-
41.9%). However, this increased Nestin (p=0.12) together with the expression of Melan 
A(p=0.12), CD271 (p=0.14) CD146 (p=0.12) and CD133 (p=0.01) were not statistically 
A B 
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significant when a Mann-Whitney test was performed. Bonferroni corrections were made to 
the comparison between NCM and PUM (p≤0.008). 
Of the ten PUM samples, five had features associated with a high metastatic risk (M3), four 
of these also having a loss of nBAP1 expression. When prognostic factors were correlated 
with the PUM results, they showed that M3 patients had a higher expression of CD271 
(median 6.8%, range 0.5-30%) compared to D3 tumours (median 4.5%, range 0.2-22.2%). 
M3 patients also had a higher Nestin expression (median 19.8%, range 9.8-98.3%) than D3 
patients (median 16.5%, range 0.04-99.3%). These changes were however not statistically 
significant when a Mann-Whitney test was performed CD271 (p=0.42) and Nestin (p=1).  
  
 
Figure 1.6. Graph showing expression of CSC markers in NCM(n=4) and PUM(n=10) cells. 
The bars represent the min-max percentage expression of the markers. The line is drawn at 
the median expression level of the markers. Statistically significant difference is shown with a 
star.  
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4.3. CSC markers are upregulated in PUM cells during anoikis resistance. 
 
Culturing cells in non-adherent/ultra-low attachment (ULA) conditions for 72 hrs ensured 
that only UM cells that were able to survive anoikis were viable. Comparison of the 
expression of CSC markers was made between the cells surviving anoikis/anchorage 
independent conditions and those grown in adherent monolayers. The UM cell lines used 
were derived from either PUM (92.1, Mel 270, MP41, MP46) or MUM (OMM1, OMM2.3, 
OMM2.5, MM66) samples. All the experiments were repeated at least 3 times and an average 
± standard deviation (SD) was calculated. This is summarised in Fig. 1.7 and Table 1.1 
below. 
Melan A, the marker of differentiated melanocytes was expressed in at least 50% of all the 
cells in both adherent and non-adherent conditions (median 73.3% vs 71.8%).    
CD271, the neural crest stem cell marker was expressed at low levels (median 1.0%, range 
0.03-33.3%) in the cells grown as adherent cultures. The cells surviving anoikis, however, 
had a higher expression of this marker (median 8.9%, range 0.04-18.2%). These changes 
were statistically significant (p<0.01, z-statistic) in MP46, OMM1, and MM66. These data 
are represented in Fig. 1.7 and Table 1.1.  
Nestin, a neural stem cell marker of prognostic significance in both skin and uveal melanoma 
(81, 82) was upregulated in all cell lines after anchorage independent growth. During 
adherent culture, the median expression of Nestin was 25.5% (range 3.0-80.4%). After non-
adherent culture, the cells had a median expression of 64.1% (range 19.8-97.5). Although this 
upregulation of Nestin expression was observed in 7/8 of the cell lines examined, these 
changes were statistically significant (p<0.01, z-statistic) only in 92.1, MP41, MP46, 
OMM2.3 and OMM 2.5. 
CD133 is a stem cell marker in hepatocellular carcinoma, colorectal cancer and glioblastoma 
(83-85). Its expression was unchanged in both culture conditions, adherent (median 0.3%, 
range 0.1-0.6%) and non-adherent (median 0.4%, range 0.2-0.8%).  
CD146 (MUC18 or MCAM) is a protein of the immunoglobulin family. It strongly expressed 
in metastatic skin melanoma cells (86) for the purpose of interacting with vascular tissue 
during haematogenous spread (87). The expression of CD146 was present in >70% of the 
UM cells and showed little change in either of the culture conditions.  
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CD166 is also a member of the immunoglobulin superfamily. It functions as a cell surface 
sensor for cell density, controlling the transition between local cell proliferation and tissue 
invasion in melanoma progression (88). Its expression was variable in the UM cell lines 
examined in adherent culture (median 34.8%, range 2.5-87.7%) and in non-adherent culture 
(median 30.5%, range 2.2-95.1%). Three of the four MUM cell lines [OMM1 (87.7-95.1%), 
OMM2.3 (3.7-6.9%), OMM2.5 (17.7-26.4%)] and one PUM; MP41 (3.1-18.0%) however, 
upregulated their expression of CD166 during anoikis resistance as compared with cells in 
adherent culture. Analyses by z-statistics showed that these changes were statistically 
significant MP41 (p<0.01) but not OMM1 (p=0.07), OMM2.3(p=0.35), or OMM2.5 
(p=0.17).    
 
Figure 1.7. Expression of CSC markers in UM cell lines cultured in adherent (plate) and 
non-adherent (ULA) conditions. The bars represent the min-max percentage expression of the 
markers. The line is drawn at the median expression level of the markers (n=3). 
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Table 1.1. Expression of CSC markers in UM cell lines grown in adherent (plate) and non-
adherent/ultra-low attachment (ULA) cultures. Numbers show mean percent (%) ± (SD) 
expression of protein markers. MUM cell lines are represented in bold. (*) samples from one 
experiment.                
 
 
4.4. Nestin, CD271 and CD166 gene expression in 80 PUM analysed by TCGA. 
 
The role of Nestin, CD271 and CD166/ALCAM gene expression in UM and their correlation 
to other prognostic factors were investigated. This was undertaken by analysing the recently-
published and publicly available data from The Cancer Genome Atlas (TCGA) for UM. It 
contains the genetic data of 80 well characterised PUM patients followed up for 5 years (53). 
mRNA expression data was obtained from the database and compared with chromosome 3 
CNVs, BAP1 gene expression and patient outcome. Analysis was done using Xena Browser 
(https://xenabrowser.net/heatmap/) and the results displayed using Corel Draw graphics 
software.  
Median expression levels of the genes (white colour) were used as the cut off points and 
upregulation was displayed in red while downregulation was displayed in blue in the heat 
maps (Fig. 1.8). The median expression levels (unit log2(fpkm-uq+1)) of the genes were: 
BAP1(19.50), ALCAM (14.22), Nestin (19.02) and CD271/NGRF (13.2). Results showed that 
UM with M3 (i.e. associated with a poor prognosis) and decreased BAP1 gene expression 
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compared to the median also had upregulations in CD166/ALCAM expression. The 
expression of Nestin and CD271/NGRF was more variable across the 80 samples with 
upregulations and downregulations occurring in the M3 as well as the D3 group in no distinct 
pattern. This is shown in the heat map of Fig.1.8 below.  
The Kaplan-Meier plots were created using the median expression levels as the cut off and 
statistics analysed by Chi-square test (𝜒2). The survival probability was calculated based on 
event (metastatic death) and time to event (number of days) as parameters. They show that 
UM expressing CD166/ALCAM above the median were associated with a poorer prognosis 
than those with expression below the median (p=0.00321). The expression of Nestin (p=0.31) 
and CD271/NGRF (p=0.68) had no statistically significant correlation with patient survival.  
CD166/ALCAM association with survival may not be as a result of its covariation with 
tumour stages (Fig. 1.9). Based on data from both the flow cytometry analyses and gene 
expression data, the functional role of CD166/ALCAM was investigated further. 
4.5. Western blotting  
 
In order to perform functional studies in UM cell lines, we purchased a CD166 antibody 
(Abcam: ab109215) that was not fluorescently-conjugated. The antibody was tested for 
antigen specificity by Western blot. The cell lysate of UM cell line Mel270 was run on an 
SDS-PAGE gel to determine CD166 protein expression. The cell line expressed CD166, 
visible as a band at the predicted molecular weight (100-105kDa) (Fig. 1.10). The antibody 
was specific for only this protein.                                            
4.6. CD166 protein is expressed in the cytoplasm of PUM cell lines by IHC. 
 
The expression pattern and cellular location of CD166 protein was examined in UM by IHC. 
Three cell lines (92.1, Mel270, OMM1) were cultured in chamber slides and stained by IHC 
for CD166. The UM cells 92.1 expressed CD166 in the cytoplasm of ~60% of the cells. The 
Mel270 cell line also showed cytoplasmic CD166 expression in approximately 40% of the 
cells (Fig. 1.10).  OMM1 cells expressed CD166 only on the membrane. This expression was 
in at least 80% of the cells. Both cytoplasmic and membrane staining for CD166 has 
previously been reported in skin melanoma (89).  
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(I) (II) 
Figure 1.8. (I)Heat map showing correlation between gene expression levels of CD166/ALCAM, Nestin and CD271/NGFR to BAP1 and Chromosome 3 
loss. The columns are (A) patient samples in rows, (B)chromosome 3 status, (C)BAP1 (D)CD166/ALCAM (E)Nestin and (F) CD271/NGFR. Blue colour 
shows downregulation, red, upregulation and white shows median expression of a gene on a log scale. Upregulation of CD166/ALCAM expression was 
more abundant in M3 UM with BAP1 downregulation while Nestin and CD271 expression was variable across the 80 PUM samples. (II)Kaplan-Meier 
survival plot showing that CD166/ALCAM expression significantly correlates with overall survival, (p=0.0032).  
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Figure 1.9. CD166 gene expression levels plotted against AJCC TNM stages for UM patients 
included in the TCGA database. CD166 expression is may not be a covariate of the tumour 
stages.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(I) 
(II) 
Figure 1.10. (I) Western blot of CD166 protein in Mel270 cells. CD166 is detected at its predicted molecular 
weight (100-105kDa) while Actin is detected at 42kDa. (II) IHC expression of CD166 in the UM cell lines (A) 
92.1, (B) Mel 270 and (C) OMM1 at 20x magnification. 
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4.7. CD166high Mel270 cells have a higher tumour transendothelial migration potential than CD166low Mel270 cells 
 
After obtaining distinct populations of CD166high and CD166low Mel270 cells by FACS (Fig. 1.11 A), the cells were plated on a layer of HUVEC 
cells cultured on transwell inserts with a 0.8µm pore size.  
The HUVECs had been in culture for three days and had formed a confluent monolayer with tight junctions between the cells. Serum was used 
as a chemoattractant in the media, with a gradient of 1% serum on top and 10% serum at the bottom. The cells with CD166high expression (mean 
25,531, median 25,474, range:17,514-3363) migrated across the HUVEC layer more than those with CD166low expression (mean 20,100, median 
20,031, range: 17,617-22,474). A Mann-Whitney test showed that the differences were statistically significant, p=0.015 (Fig. 1.11 B). 
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Figure 1.11. (A) Flow cytometry profile of Mel 270 cell line. The cells positive for CD166 (40.1%) are shown. (B) Bar graph representing the number 
of Mel270 tumour cells migrating across the HUVEC and the insert layer. The experiment had six technical replicates and Mean±SD is shown. A 
Mann-Whitney test shows that extravasation was significantly (*) higher in CD166high compared to CD166low cells, p=0.015.        
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4.8. CD166 is expressed in the cornea, ciliary body and optic nerve 
 
IHC staining undertaken in eyes enucleated due to the presence of UM, revealed several 
normal ocular structures that expressed CD166. These served as an internal positive control 
when examining the tumour cells. They include the corneal epithelium, ciliary processes and 
ciliary muscle, trabecular meshwork and the meningeal layer of the optic nerve (Fig. 1.12).         
                         
Figure 1.12. Representation of the CD166+ structures in the eye. (A) cornea epithelium; (B) 
the ciliary processes; (C) trabecular meshwork; and (D) the meningeal layer of the optic 
nerve. 
 
4.9. IHC analysis shows that CD166 is expressed in the PUM tissue. 
 
IHC staining was performed in FFPE sections obtained from enucleated eyes of PUM 
patients. These are the same tumour samples used for STC and subsequent analysis by flow 
cytometry. The antibody used for IHC (Abcam: ab109215) was different than that used for 
flow cytometry (Biolegend: 343904) and was optimised before use. The specificity of this 
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antibody was also examined by Western blot as shown above. Melan A-stained slides of 
these tissue sections were obtained from the pathology archives and used to identify the UM 
cells. The identified PUM cells were then examined for CD166 expression.  
PUM cells stained for CD166 in both the cytoplasm and the membrane. This was clearly 
observed in only two of the nine samples examined (eight were from enucleations and one 
was from an endoresection). In one of the samples, the staining was weak and involved only 
the anterior one-third of the tumour (Fig. 1.13 A, B). In this region, 70% of the UM cells 
stained positive for CD166 while tumour cells in the posterior two-thirds of the tumour were 
negative. It was difficult to determine cytoplasmic or membranous staining in the heavily 
pigmented or macrophage dense UM sections (4/9).  
In addition to positive staining for CD166 in the tumour cells it was also detected in the 
cytoplasm of the tumour associated macrophages (Fig. 1.13 C). Normal pancreas sections 
stained positively for CD166 in the islets of Langerhans (Fig. 1.13 D). The NCM expressed 
membranous and cytoplasmic CD166 (Fig. 1.13 E). Endothelial cells in some tumour 
sections also stained positive for CD166 (Fig. 1.13 F).  
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Figure 1.13. (A) PUM tissue from an enucleated eye with positive staining for CD166 in the anterior one-third (bold black arrow) and negative 
staining in the posterior two-thirds (star) are shown. (B) Higher magnification of the anterior region showing membranous (thin black arrows) 
and cytoplasmic staining of PUM cells. (C) Posterior two-thirds (star) shows the negative staining of PUM cells and positive macrophage 
CD166 stain. (D) Positive control stain in the pancreas. (E) CD166 positive normal melanocytes. (F) Positively-stained endothelial cells and 
macrophages from the PUM tumour section. 
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4.10. Neural crest markers are expressed in PUM 
  
Evidence from skin melanoma shows that similar pathways and features are employed during 
malignant transformation and metastasis as those found in the embryonic NC cells. These 
include EMT, migration through different microenvironments and expression of NC 
regulatory factors/markers (90). Our hypothesis was that UM cells reactivate developmental 
pathways that control cell proliferation and migration. One of the aims of this study was to 
investigate if the developmental/neural crest markers are expressed in UM tissue. We focused 
on MITF, SOX10, PAX3, Notch 1 and Nestin, all which play a role in melanocyte 
development as shown below in (Fig. 1.14). 
 
 
Figure 1.14. Key regulatory signalling pathways involved in melanocyte development. Wnt, 
End3 and KIT activate MITF expression which then leads to melanocyte proliferation, 
survival and differentiation. Notch1 prevents apoptosis of melanoblasts and maintains 
melanocyte stem cells. SOX10 enhances Nestin gene expression resulting in increased 
migration and invasiveness of melanoma cells (Image adapted from Hou L et al. 2008(91)). 
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IHC analysis showed that MITF, SOX10 and PAX3 are expressed in the nuclei of >80% of 
PUM cells in all six samples. The Notch1 antibody used detects activated Notch1 and is thus 
used to mark nuclear Notch 1 expression. Activated Notch1 was also expressed in the nuclei 
of >80% of PUM cells in all six samples (Fig. 1.15). There was no difference in the 
expression pattern of these markers when high-risk M3 tumours were compared to the low-
risk D3 tumours. Poor prognostic features such as the presence of loops and epithelioid cells 
were seen in some of the M3 tumours, but this did not influence the expression of these 
markers.   
C-KIT was expressed on the cell membrane of PUM in both the M3 and D3 tumours. It was 
expressed in >70% of cells in the M3 tumours and <50% of cells in the D3 tumours. Nestin 
was expressed only in the endothelium of the blood vessels of the D3 samples, with no 
expression in the tumour cells (Fig. 1.15). In the M3 UM, Nestin expression was evident in 
the membrane and cytoplasm of the tumour cells. Of the markers examined, C-Kit and Nestin 
showed variation in expression between the high and low metastatic risk tumours.  
Overexpression of C-KIT in UM has been previously described (92) and a therapeutic agent 
(imatinib mesylate) acting against this tyrosine kinase inhibitor has been tested in a phase II 
multicentre clinical trial involving patients with unresectable MUM. The trial showed no 
effect of the drug and the clinical trial did not proceed to the next stage (93). Further 
investigations to the mechanism responsible for drug resistance in this trial showed that stem 
cell factor (SCF), a cytokine produced in the hepatic tumour microenvironment mediated 
imatinib resistance by competitively binding to the KIT receptor. This binding led to a 
conformational change of the receptor preventing stable binding of imatinib mesylate 
(93).Although C-KIT expression showed variation between M3 and D3 tumours in this study, 
it was not examined further. An investigation of Nestin, which had showed a distinct 
difference between M3 and D3 tumours was undertaken in a larger cohort of PUM samples, 
MUM and UM cell lines.  
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Figure 1.15. Neural crest markers are expressed in PUM tissue. MITF, SOX10, PAX3 and 
Notch 1 are expressed in the nucleus of the PUM cells. C-Kit and Nestin are expressed in the 
membrane of PUM cells. D3 =Disomy 3 and M3= Monosomy 3. DAB chromogen (brown) 
was used to indicate positive staining and images were taken at 10x magnification. 
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4.11. Nestin expression in vitro  
A western blot was performed using two UM cell lines to determine the specificity of the Nestin antibody used. Nestin was expressed in the 
Mel270 and MM66 UM cell lines. It is visible at a higher molecular weight (~250kDa) (Fig. 1.16) than the predicted 177kDa, however this is 
consistent with data provided by the manufacturers and also as reported on www.proteinatlas.org/ENSG00000132688-NES/antibody, which 
reports a WB band of around 250kDa and interaction of the antibody only with its own antigen on protein array. A preliminary IHC staining of 
six UM cell lines was also undertaken. Nestin was expressed in the cytoplasm as well as the membrane of these cell lines (Fig. 1.16). Following 
this a large cohort of PUM samples (144) were stained for Nestin.  
Mel 270 MM66 
225 kD 
 
150 kD 
 
 102 kD 
 
   76 kD 
Figure 1.16. (I) Western blot showing Nestin expression in Mel270 and MM66 UM cell lines. (II) Nestin protein expression as determined 
by immunocytochemistry in the cytoplasm and membrane of six UM cell lines. Positive staining is shown by AEC chromogen (red). Images 
were taken at 10x magnification.  
 
(I) (II) 
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4.12. Nestin expression in PUM  
 
144 PUM samples underwent IHC staining for Nestin. The results were scored on a 0-100% 
scale for positively stained tumour cells. Nestin was positive in several non-tumour areas of 
the globes and these were used as positive internal controls to validate the IHC stain 
alongside the normal control colon sections. These areas include the cells of the neuroretina, 
the inner and outer nuclear layer, the ganglion cells and optic nerve fibre layer (Fig. 1.17A). 
The blood vessels were also Nestin positive. The retinal pigment epithelium and the NCM 
did not express Nestin (Fig. 1.17, B). 
Melan A-stained slides of the tissue sections obtained from the pathology archives were used 
to identify the UM cells across the tissue sections, and to determine the quality of 
immunostaining of the samples following formalin fixation. The identified UM cells were 
then examined for their Nestin expression. The UM cells expressed Nestin in their membrane 
and cytoplasm. The endothelium of the intratumoural blood vessels were also positive for 
Nestin in some tissue sections (Fig. 1.17D). To determine the highest levels of sensitivity and 
specificity for Nestin expression, a ROC analysis was performed. The data identified that a 
range of expression between 8.5% (0.857/0.584; sensitivity/specificity) and 12.5% 
(0.679/0.478; sensitivity/specificity) would give the highest sensitivity and specificity 
respectively at 95% confidence interval (CI). A 10% threshold was therefore used as the cut-
off point. Previous studies examining Nestin had also used this threshold (94). UM samples 
with <10% Nestin expression (Fig. 1.17C) were thus considered negative for this marker.  
Fifty-two of 141 (36%) of the examined PUM were scored as negative for Nestin expression. 
Sixty-three PUM (44%) showed varying intensity of Nestin expression ranging from 10-50% 
positivity in the tumour cells (Fig. 1.17 E, F). Nestin was expressed in 50– 100% of UM cells 
in the remaining 26 PUM samples (18%). In these samples, Nestin was expressed both in the 
cytoplasm and membrane of cells (Fig. 1.17 G, H). Positive staining in the endothelium of 
the intratumoural blood vessels was observed in a total of 36 PUM (25%).  
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Figure. 1.17. (A) Nestin expression in the neuroretina, inner, outer nuclear layer and the optic nerve layer. (B) The choroidal melanocytes and 
retinal pigment epithelium are negative for Nestin. (C) PUM tissue section with <10% of tumour cells expressing Nestin. (D) The intratumoural 
capillary endothelium tissue expressed Nestin. (E, F) PUM tissue sections expressing Nestin in 10–50% of the cells. (G, H) Nestin expression in 
>50% of cells (All images are at 10x magnification). Insets show staining at (40x magnification). 
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4.13. Survival analysis  
 
When correlated with known poor prognostic factors in PUM (58-60), Nestin positivity 
(≥10%) was significantly associated several predictors of metastasis. These include 
epithelioid morphology (Pearson’s Chi-square p<0.0001), high mitotic count (Mann–
Whitney p<0.0001), closed connective tissue loops (Pearson’s Chi-square p=0.001) 
monosomy 3 (Pearson’s Chi square p=0.007) and chromosome 8q gain (Fisher’s exact test 
p<0.0001). Increasing Nestin expression was significantly correlated with the absence of 
nBAP1 protein expression (p=0.015, Mann–Whitney) (Fig. 1.18A). Nestin expression in the 
capillary endothelium showed no significant correlation with any prognostic factor. Patients 
with PUM classified as negative for Nestin expression (<10%) had a better prognosis than 
those patients with positive Nestin expression in the tumour cells as shown by the Kaplan–
Meier analysis (Fig. 1.18B; Log-rank p = 0.002). 
4.14. Nestin expression in MUM 
 
Melan A-stained slides of MUM were obtained from the Pathology archives and assessed, 
similarly to the PUM described above. They were used as a reference to show the antigenicity 
of the tissue and to identify the tumour cells. The hepatocytes and hepatic stellate cells did 
not express Nestin while the MUM cells and associated blood vessels were positive for 
Nestin. nBAP1 data were available for 19 of the 26 MUM; 17 MUM were negative for 
nBAP1 expression and two were positive for nBAP1.  
50-100% of Nestin positive tumour cells was were seen in ten of the 26 MUM (38%) (Fig. 
1.19 A). Nine of the 26 samples (34%) had 10-50% of Nestin expressing cells. In 17 (65%) of 
the samples, Nestin was expressed in the UM cells located within closed connective tissue 
loops (Fig. 1.19 B). Six (23%) of the 26 MUM had <10% Nestin-expressing tumour cells 
(Fig. 1.19 C), and in one other, Nestin expression was completely negative. Nestin 
expression in the intratumoral capillary endothelium was visible in nine MUM samples which 
also showed a high proportion (50-90%) of Nestin-positive melanoma cells in the tissue (Fig. 
1.19 D).  
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Figure 1.18. (A)Correlation of Nestin with clinical and prognostic factors. LBD= Largest basal diameter, UH=Ultrasound, CBI=Ciliary body 
involvement, EOE= Extraocular spread. (B)Kaplan–Meier survival curve and table for all PUM stratified according to Nestin expression. 
Nestin expression ≥10% was associated with poor outcome (Log rank p=0.002). No. of events indicates the number of deaths from metastatic 
UM.
A B 
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Figure 1.19. Representative images of Nestin expression in MUM (10x magnification). Insets 
show Nestin expression at 40x magnification. (A) and (B) show a high proportion of Nestin-
expressing UM cells both inside closed connective tissue loops and outside. (C) shows only a 
few Nestin-positive cells, while (D) shows Nestin expression in the capillary endothelium of 
the MUM.  
A 
C 
B 
D 
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4.15. Nestin expression in matched PUM-MUM 
 
Scattered UM cells that were located away from the bulk of the tumour in the MUM sections 
also stained positive for Nestin. Eleven of the MUM samples had matched PUM sections 
available. When examined, Nestin was expressed in the cytoplasm of the UM cells in all the 
PUM tissue sections (Fig. 1.20B). In one (9%) PUM, there were <10% of Nestin positive 
cells in the tumour section. Eight (72%) of the eleven PUM had 10-50% of Nestin expressing 
cells while in the remaining two samples (18%), Nestin was expressed in 50-90% of the PUM 
cells. In five of these PUM samples, staining was also seen in the intratumoural capillary 
endothelium. Nine of these matched PUM were negative for nBAP1 expression, one was 
positive and for one, data were not available.  
A varied expression of Nestin was seen in the MUM: four MUM (36%) expressed Nestin in 
>50% of the tumour cells (Fig. 1.20D), three (27%) expressed Nestin in 10–50% of UM 
cells. In two (18%) other samples, only scattered large ovoid MUM cells stained positive for 
Nestin (Fig. 1.20H). Only the intratumoural capillary endothelium stained positive for Nestin 
in the remaining two samples (18%). Seven of these MUM were negative for nBAP1 
expression, two were positive while the BAP1 expression data were unavailable for the 
remaining two samples. 
 Interestingly, three of the four MUM samples with >50% of cytoplasmic Nestin-expressing 
cells had shorter metastasis free and overall survival than the MUM in which Nestin 
expression was <50%. One of the patients died 2 weeks after the diagnosis of metastatic 
melanoma while the two others died within one month of diagnosis. The fourth patient is still 
alive with features of good prognosis such as nuclear BAP1 expression in the PUM and a 
normal (disomy) chromosome 3 status. The MUM cells in the liver resection are also nBAP1 
positive for this patient. The three-remaining matched M3 PUM and MUM were negative for 
nBAP1 expression. 
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Figure 1.20. Nestin expression in two representative matched PUM-MUM. A, C, E and G are H&E-stained images. B, D, F and H show Nestin 
expression. A high proportion (>50%) of Nestin-expressing tumour cells are seen in both (B) PUM1 and (D) MUM1 from the same patient. 
Nestin expression was noted in tumour cells of (F) PUM2 contained within large closed connective tissue loops. (H) MUM2 showed Nestin 
expression in large ovoid tumour cells. PUM2 and MUM2 are from the same patient.  
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5.Discussion  
This study has shown the expression of CSC markers in UM. Flow cytometry results have 
demonstrated increased expression of the CSC markers, Nestin, CD271 and CD166 in high 
metastatic risk PUM compared to low metastatic risk PUM and NCM. The ability of a 
subpopulation of UM cell lines to escape anoikis by upregulating stemness markers such as 
CD166, CD271 and Nestin provides further evidence for the existence of CSCs in UM. This 
study has also shown that protein markers associated with NC developmental pathways 
leading to melanocyte specification are expressed in UM, suggesting that these primitive 
pathways may be reactivated in this tumour. These markers, including MITF, SOX10, PAX3, 
Notch 1, C-KIT and Nestin, have been shown to play a role in the tumourigenesis and 
metastasis of several cancers, particularly skin melanoma. They may function in a similar 
manner in UM. 
Studies in skin melanoma have shown a higher overall expression of CD166 in primary 
tumours than benign lesions by IHC (95, 96).  Consistent with these studies, flow cytometry 
analysis showed that PUM expressed more CD166 compared to NCM. Nestin expression was 
also higher in the PUM compared to the NCM, consistent with previous reports in literature 
(82). The findings of Lai et al. who examined expression of CD146/MCAM/MUC18 in the 
uvea support the CD146 results in this study (97). They reported that CD146 is expressed in 
the NCM, FFPE tumour sections and UM cell lines. This membrane marker has since been 
included in the FDA-approved Cell Search system for isolation of circulating melanoma cells 
in the blood (98, 99). However, the high levels of expression of this marker in both UM and 
NCM suggest that it lacks specificity as a CSC marker. 
Anoikis is an apoptotic cell death process induced in cells after their detachment from the 
extracellular matrix (ECM) (100). It is a physiological process that prevents attachment and 
seeding of displaced cells at inappropriate sites. Resistance to anoikis is a hallmark of 
tumorigenesis and metastasis, as it enables cancer cells to survive and spread in the blood or 
lymphatic system (100). The different causes of anoikis resistance in cancer cells, include 
genetic instability, intra-tumoral hypoxia, epithelial-mesenchymal transition and 
overexpression of stemness markers (101). Overexpression of stemness markers activates 
processes including cell proliferation, survival, motility, migration, apoptosis and anoikis 
resistance (100). CSCs in several cancers including breast have been shown to be resistant to 
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anoikis, form spheres in non-adherent culture and have enhanced tumour growth capacity 
(102).  
In this study, UM cell lines surviving anoikis showed an increased expression of several 
markers previously associated with neural crest development and stem cells: CD271, Nestin 
and CD166. The CSC population in skin melanoma has been shown to express CD271 (103). 
Samples having >5% of CD271/SOX10 positive cells correlated with poor tumour specific 
survival. CD271+ cells were able to form tumours in xenograft models that resembled the 
parent tumour. The range of CD271 expression was 4.1-5.9% in these tumour cells from 
passage one to passage five xenografts (103). In UM, CD271 was also expressed in the cells 
that formed vasculogenic mimicry patterns, a poor prognostic feature likely to cause 
metastasis (20). In this study, CD271 was upregulated (median 8.9%) in the cells surviving 
anoikis compared to cells in adherent culture (median 1.0%). Its expression was also higher 
in M3 tumours (median 6.8%) compared to D3 tumours (median 4.5%) suggesting its role in 
selecting for the CSC population. 
Nestin was identified as a marker of skin melanoma stem cells along with CD133 and 
CD166. It was expressed at moderate to strong intensity in >15% of cells of the primary and 
metastatic melanomas but not nevi (95). Nestin protein and mRNA expression were also 
described in UM cell lines and primary tissue in the study investigating putative CSCs in 
UM. The CD133+/Nestin+ cells ranged from 3.1-17.6% in Mel270, OMM2.3 and OMM2.5 
UM cell lines by FACS analysis (104). Although the CD133+/Nestin+ double positive cells 
were not examined in this study, the presence of Nestin in the UM cell lines supports the 
findings of the study by Thill et al (104). These results suggest that PUM cells surviving 
anoikis may be enriched by the CSC population, as evidenced by their increased expression 
of stemness markers. 
In the PUM tissue sections stained by IHC, CD166/ALCAM expression was abundant in the 
cytoplasm of the tumour associated macrophages. These results support those of Levesque et. 
al who showed that CD166/ALCAM is expressed in the macrophages of arthritis patients in 
response to cytokine release (105). Variable CD166 staining was also observed in 
macrophages in the study by van Kempen et al. examining ALCAM expression in skin 
melanoma (89). Tumour endothelial cells also expressed CD166/ALCAM, which has been 
reported to be involved in early embryonic haematopoiesis and vasculogenesis (106). In this 
study, expression of CD166/ALCAM in the PUM cells analysed by IHC was not as abundant 
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as demonstrated by flow cytometry. The presence of CD166 positive macrophages and 
endothelial cells may account for this. However, its location was similar to that in skin 
melanoma, being positive both in the membrane and the cytoplasm of the tumour cells (89).  
CD166/ALCAM was expressed in several normal structures of the eye including the normal 
choroidal melanocytes. This had only been previously reported in the choroid of mice 
although its role is yet to be established (107). The ciliary muscle and ciliary processes also 
strongly expressed ALCAM in their membrane. Additionally, the trabecular meshwork also 
had ALCAM positivity. Implications of the glaucoma disease process and possible drugs may 
be drawn from these results. Expression of ALCAM in the corneal endothelium has 
previously been reported, both in vivo and in vitro (108, 109). Similarly, ALCAM is 
important in neurogenesis and in supporting neurite extension (110). It is expressed in spinal 
cord motor neurons and those of the peripheral nervous system (111). Its expression in the 
body and meninges of the optic nerve was therefore anticipated. Further investigations are 
necessary to ascertain if these data may be of clinical relevance. Our findings also present 
new insights into the expression of CD166 in the other structures of the eye, which have not 
been reported previously.  
In this study a detailed examination of Nestin expression in PUM and MUM was also 
performed. The results show that Nestin expression is associated with a reduced survival time 
in UM. Nestin expression also significantly correlates with known poor prognostic factors in 
PUM, such as epithelioid cell morphology, high mitotic count, the presence of closed 
connective loops, monosomy 3 and polysomy 8q.  
 Gene expression profiling has shown that these poor prognostic parameters are also 
associated with so-called high metastatic risk ‘class 2’ UM (112). These class 2 PUM express 
genes similar to those seen primitive neuroectodermal and neural crest cells. The authors 
suggest that class 2 PUM have cells with primitive stem-like cell phenotype (113). Nestin is 
expressed in the migrating and proliferating neuroectodermal cells during embryogenesis. In 
adult tissues, it may identify primitive multipotent cells with regenerative capacity that can be 
re-activated during injury (114).  
The absence of Nestin positivity in NCM as compared to its presence in UM cells may 
suggest reversion to a more primitive phenotype during tumourigenesis. This theory may be 
supported by evidence from recent studies in several tumours, including cutaneous 
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melanoma, squamous cell carcinoma, basal cell carcinoma, osteosarcomas and gliomas (115-
117) that have associated increased Nestin expression with an immature and invasive cell 
phenotype. Data from this thesis also supports these findings. Nestin expression was higher in 
the PUM compared to NCM as well as in M3 tumours (higher metastatic risk) compared to 
D3. The Nestin expressing UM cells may represent a subpopulation with stem cell-like 
characteristics.  
In support of this, data generated by The Cancer Genome Atlas (TCGA)-UM study (53) and 
from the analysis of gene expression data previously generated by Laurent et al.(118), 
showed that Nestin mRNA expression was identified in a panel of genes associated with 
reduced time to metastasis after diagnosis of the PUM. However, this association was not 
found to be significant when examining the hazard ratio and 95% CI (118). This may be due 
to the relatively small cohort examined by the TCGA (n = 80), as compared to the 141 PUM 
examined in the current study.  
The presence of putative CSC with self-renewal capacity that were resistant to chemotherapy 
was previously reported in UM cell lines (119). Nestin expression has been shown in the 
tissue of melanoma patients as well as in their circulating tumour cells (CTC). An analysis of 
the blood obtained from both cutaneous and UM patients revealed Nestin-expressing cells, 
which were absent in healthy volunteers (120). 17 skin melanoma patients with stage IV 
disease had Nestin mRNA expression in their blood samples compared to 4 stage III/II 
patients. Nestin mRNA expression was also significantly (p=0.041) higher in the blood 
samples of patients with high versus low tumour burden (121). This strongly proposes the 
possible use of Nestin as a biomarker for early detection of metastatic disease in high-risk 
UM patients. Its sensitivity may be more than that of previously proposed serum biomarkers, 
such as osteopontin, S100B and melanoma inhibitory activity (MIA). Nestin may be added to 
the panel of sensitive serum biomarkers of MUM along with the proposed cytokeratin 18 
(122) and GDF-15 (123).  
The molecular function of Nestin has also been investigated in several cancers. Suppression 
of Nestin expression by shRNA in cutaneous melanoma cell lines has been shown to lead to 
reduced cell growth, migration and invasion into Matrigel (124). These cells also have less 
spheroid formation ability than the control. When these cells were injected into mice, they 
formed smaller tumours, which did not metastasize to the liver (124). In gliomas, similar 
results were observed following Nestin knockdown (125). In pancreatic ductal carcinoma, 
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Nestin downregulation inhibited liver metastasis in vivo (126). In UM, further functional 
studies are necessary to help us to delineate the role of Nestin. In this regard, Nestin IHC has 
been undertaken in a panel of six UM cell lines to determine baseline expression of this 
protein. Several UM cell lines with high levels of Nestin expression (e.g. 92.1, Mel270 and 
MP41) have been identified. These may then be used to create isogenic cell lines for in vitro 
functional assays. These assays have been included in our future plans.  
In conclusion, the present study shows that UM contains a population of cells with 
characteristics of CSCs in vitro. In particular, CD166high UM cells may represent a 
subpopulation with enhanced migratory capacity. Our future plans include using in vivo 
models to investigate if these findings can be recapitulated in living organisms. Additionally, 
this study has suggested that developmental pathways may be activated in UM cells, 
evidenced by the expression of NC and melanocytic lineage markers in PUM samples. PUM 
samples with >10% of Nestin-expressing cells correlate with poor survival. Nestin is also 
expressed in MUM, which together with previous studies showing Nestin expression in CTC, 
suggests that Nestin may be used as a biomarker in high-risk UM patients for early detection 
of disseminated disease. It is possible therefore that UM CSCs may be identified using 
several markers including CD166 and Nestin. 
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